Whole-Exome Sequencing Identifies Mutated C12orf57 in Recessive Corpus Callosum Hypoplasia  by Akizu, Naiara et al.
REPORT
Whole-Exome Sequencing Identifies Mutated
C12orf57 in Recessive Corpus Callosum Hypoplasia
Naiara Akizu,1 Nuri M. Shembesh,2 Tawfeg Ben-Omran,3 Laila Bastaki,4 Asma Al-Tawari,5 Maha S. Zaki,6
Roshan Koul,7 Emily Spencer,1 Rasim Ozgur Rosti,1 Eric Scott,1 Elizabeth Nickerson,8 Stacey Gabriel,8
Gilberto da Gente,9 Jiang Li,9 Matthew A. Deardorff,10,11 Laura K. Conlin,12 Margaret A. Horton,10
Elaine H. Zackai,10,11 Elliott H. Sherr,9,* and Joseph G. Gleeson1,*
The corpus callosum is the principal cerebral commissure connecting the right and left hemispheres. The development of the corpus
callosum is under tight genetic control, as demonstrated by abnormalities in its development in more than 1,000 genetic syndromes.
We recruited more than 25 families in which members affected with corpus callosum hypoplasia (CCH) lacked syndromic features
and had consanguineous parents, suggesting recessive causes. Exome sequence analysis identified C12orf57 mutations at the initiator
methionine codon in four different families.C12orf57 is ubiquitously expressed and encodes a poorly annotated 126 amino acid protein
of unknown function. This protein is without significant paralogs but has been tightly conserved across evolution. Our data suggest that
this conserved gene is required for development of the human corpus callosum.The corpus callosum (CC), the largest commissural white-
matter tract in the mammalian brain, is essential for
interhemispheric integration of sensory, motor, and
higher-order cognitive information. It is traditionally
divided into four segments, the rostrum, genu, body, and
splenium. Development of the CC occurs during weeks
6–20 of gestation, and developmental defects, observed
in 0.3%–0.7% of individuals undergoing brain imaging,
are among the most common of brain malformations.1
Abnormalities of the CC are noted in more than 1,000
unique OMIM entries, suggesting that CC development
is very sensitive to genetic perturbations. Additionally,
twin studies have suggested a high heritability of the CC
area.2 However, well-described disorders that specifically
affect the CC in the absence of other major abnormalities
are quite rare.
We previously described subtypes of CC abnormalities
after having conducted detailed structural analysis from
brain MRI scans from a cohort of 30 affected individuals
from 19 families with a history of parental consan-
guinity.3 The initial presenting feature was developmental
delay or epilepsy in all cases,4 and brain MRIs showed CC
abnormalities without othermajor neuroanatomic defects.
We focused on parental consanguinity to enrich the study
for cases that were likely to involve recessive inheritance,
in which phenotypes were more likely to be fully expres-
sive and fully penetrant. We delineated onemajor category
consisting of CC hypoplasia (CCH) without dysplasia.
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share a single homozygous-recessive allele, siblings can
display a spectrum of severity ranging from almost normal
appearance to complete agenesis. The data suggest that
there might be wide-ranging phenotypic severity even
with presumably identical genetic mutations in siblings
and that complete agenesis might be a common end
phenotype.
For this study we prioritized families for genetic analysis
by focusing on those with first- or second-degree consan-
guinity and two or more affected members in the setting
of CCH; these criteria made it likely that a recessive genetic
origin was involved. All family members underwent
a routine clinical brain MRI, including midline sagittal
and axial views. After worldwide recruitment of individ-
uals identified from 1999–2012 as having neurodevelop-
mental disease, we focused on those for whom a brain
MRI either showed isolated CCH or showed CCH as the
major imaging anomaly. Individuals with other major
structural brain anomalies or overwhelming evidence of
other dysmorphic or syndromic causes were excluded.
We genetically evaluated 27 families, four of which were
simplex. The remaining familes, including the previously
ascertained 19 families, were multiplex with similarly
affected siblings. The study was approved by appropriate
ethics committees, and the families provided informed
consent.
We used QIAGEN reagents to extract blood DNA, in
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scan on all informative family members by using the
Illumina Linkage IVb mapping panel.5 We analyzed the
DNA with easyLinkage-Plus software6 to calculate multi-
point LOD scores. In each family, we generated whole-
exome sequence on two affected individuals if two were
available (20 families), one affected individual plus both
parents in simplex families (four families), or a single
affected individual from either type of family (three fami-
lies). We used the Agilent SureSelect Human All Exome
50 Mb kit to capture exomes and an Illumina HiSeq2000
instrument to sequence them, resulting in ~94% recovery
at >103 coverage. We used the Genome Analysis Toolkit7
for SNP and INDEL variant identification and SeattleSeq
for annotation. We then filtered out variants that were
represented with an allele frequency of more than 1%
in dbSNP, the Exome Variant Server, or our in-house exome
data set of 1400 individuals (dbGaP study ID phs000288).
Finally, we prioritized the variants according to scores from
prediction programs (PolyPhen, Grantham, Phastcon, or
Genomic Evolutionary Rate Profiling).8–11
Two families had mutations in genes already associated
with diseases. Family 566 included two affected girls
from a first-cousin consanguineous marriage, resulting in
four unaffected children. Brain MRIs showed that the
affected individuals had CCH, and they also displayed
profound developmental delay, visual and motor impair-
ment, and hypogenitalism, and the older child had micro-
cornea; all of this suggested possible Warburg Micro
syndrome (MIM 600118). CCH is one of the major find-
ings in Warburg Micro syndrome,12 and not surprisingly,
in both affected individuals exome sequencing identified
a chr2:135890463A>G homozygous variant at the canon-
ical splice-acceptor site for exon 11 of RAB3GAP (Refseq
accession number NM_001172435.1), a gene mutated in
this condition.13 Family 1158 included doubly consan-
guineous parents and three affected children, all three of
whom displayed CCH, epilepsy, and delayed milestones.
There was evidence of mild progressive symptoms, but
metabolic studies were negative. Linkage analysis demon-
strated a single linkage peak at chr18q11.2 with maximum
LOD score 3.62. Exome sequenceing of two affected indi-
viduals identified a shared chr18:21148840G>A homozy-
gous variant, predicting a p.Thr137Met transversion in
a conserved threonine in NPC1 (RefSeq accession number
NM_000271.4). NPC1 mutations lead to Niemann-Pick
type C disease (MIM 257220), a neurovisceral disorder
characterized by lysosomal accumulation.14 The major
features, including upgaze nystagmus and organomegaly,
were not prominent in these individuals, whereas mild
phenotypes and CCH are well documented.15–17 These
data support the finding of CCH as a part of many
described conditions.
Although the remaining families had potentially causa-
tive variants, for only one gene were we able to validate
the association in two independent CCH-affected families.
In these families (542 and 1414; Figure 1), we identified
a homozygous variant, chr12:7053285A>G, predicted toThe Ameresult in substitution of the initiator methionine of
C12orf57 (c.1A>G, p.Met1?, Refseq accession number
NM_138425.1, Entrez ID uc001qrz.3). Family 542, from
Kuwait, consisted of first-cousin parents and nine children,
three of whom were similarly affected. Family 1414, from
the Eastern part of Libya, consisted of nine living children
from11pregnancies (onewith twins); two of these children
were similarly affected. Concurrently, we identified two
additional consanguineous multiplex families with the
same chr12:7053285A>G mutation in C12orf57. Family
1183, clinically reported,18 presented with four healthy
individuals and two affected individuals with CCH, optic
coloboma, craniofacial, and skeletal abnormalities reminis-
cent of Temtamy syndrome (MIM 218340). The family was
of Palestinian origin and displayed parental consanguinity.
Family EZ1, from the United Arab Emirates, consisted of
first-cousin parents and six living children, three of
whom were similarly affected. One other child had died
in adolescence from unrelated causes. Using similar
methodology to perform whole-exome sequencing in two
affected members per family led to independent identifica-
tion of this mutation in both of these families. In family
542, we performed SNP analysis of six of the children and
both parents by using the Illumina 5K Linkage IVb
mapping panel5 to generate LOD scores under a strictly
recessivemode of inheritance and identified several linkage
peaks with pLOD scores of more than 3.0 on chromosomes
2, 10, and 12 (Figure 1E), which included C12orf57. In
family EZ1, we performed SNP analysis by using the
Illumina OMNI1 Quad platform on three affected indi-
viduals and three unaffected individuals and identified
several loci of homozygosity; one of these was at chr12:
6488450–23121965 (Figure S1 in the Supplemental Data
available with this article online). Thus, the linkage and
genotyping data from the two families analyzed with SNP
array was consistent with a locus containing C12orf57.
The clinical phenotype included hypotonia, moderate to
severe intellectual disability, and various forms of epilepsy
in eight of the ten affected members (Table 1). Four of the
ten affected individuals showed evidence of abnormal
visual function; such evidence included documented optic
atrophy, coloboma, or an abnormal visual evoked poten-
tial. All ten individuals displayed autistic features, such as
clinical automatisms, absent language, and poor social
interactions. The two individuals in family 1183 had
lower-extremity spasticity in conjunction with truncal
hypotonia. Thus, the clinical phenotype is nonspecific.
The affectedmembers in the four families displayed clear
and specific abnormalities of the corpus callosum
(Figure 2); these abnormalities fell within the spectrum of
hypoplasia to agenesis. In two individuals from family
EZ1, imaging was not available for review. The CC was
absent in three of the remaining eight individuals and
hypoplastic in five. In family 542, the two older members
(III-3 and III-5) displayed CC hypoplasia. Interestingly, the
youngest affected member (III-9) displayed complete agen-
esis of the CC. In family 1414, the older individual (III-1)rican Journal of Human Genetics 92, 392–400, March 7, 2013 393
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Figure 1. Families 542, 1414, 1183, and EZ1 with a Homozygous C12orf57Mutation Encoding a p.Met1? Substitution Leading to CCH
(A–D) Pedigrees demonstrating affected and unaffected individuals, all from first-cousin marriages. An asterisk indicates that DNA was
ascertained.
(E) Multipoint linkage plot resulting from the analysis of a 5K SNP array performed in all members of 542. Highest pLOD scores were
found in chromosomes 3, 10, and 12. A red arrow indicates the location of C12orf57.
(F) Invariant conservation of the Met1 amino acid position of the predicted protein (red arrow). Nonconserved amino acids are in gray.displayed CC hypoplasia, whereas the younger individual
(III-12) displayed complete agenesis. In family 1183, the
youngest child had complete callosal agenesis, and the
older sibling had partial agenesis of the CC. Individual
1183-III-6 had a midline colloid cyst in the anterior aspect
of the third ventricle; this cyst could be incidental ormight
suggest an underlying midline defect. In each member,
notable hypoplasia of the thalamus produced a V-shaped,
enlarged third ventricle, best appreciated in coronal images
(Figure S2). When we evaluated the remaining 25 families
from our CCH cohort, we found no others with this
specific third-ventricle defect. Furthermore, enlargement
of the third ventricle was apparent in only 2% of the
more than 800 brain MRI scans in the UCSF Brain Disorder
Research Program database, suggesting a highly specific,
possibly pathognomonic radiographic hallmark.
We confirmed the mutation on the basis of Sanger
sequencing in the affected members in all four families,
and we additionally confirmed that the mutation segre-
gated according to a strictly recessive model with full pene-
trance. All tested parents were heterozygous carriers (one
parent in family 1183 was unavailable for testing), whereas
the unaffected siblings were either heterozygous or homo-
zygous wild-type. The mutation was not identified in any
other individuals from more than 1,400 individuals for394 The American Journal of Human Genetics 92, 392–400, March 7whom whole-exome sequencing was available (of these
1,400, ~1,000 are of matching Arab descent), nor was it
evident in any public SNP database. There were no other
potentially deleterious variants in this gene in our CCH
cohort. We also tested an ethnically matched Kuwaiti
and Libyan cohort of 100 control individuals each—
Kuwait and Libya are the countries of origin for family
542 and 1414, respectively—and found no carriers for
the mutation. Furthermore, other variants identified
from exome sequencing were either nonconserved or did
not segregate according to a recessive mode of inheritance
in family 542 or 1414 (Table S1). For family 1183, only one
other variant that we tested from the exome report was
found to segregate appropriately, in ANKMY1 (Refseq
accession number NM_016552.2), but mutations in this
gene were not encountered in any of the other families.
The data were consistent with the C12orf57 c.1A>Gmuta-
tion’s being causative in these four families.
Because the four families were of Arab descent, although
of different geo-ethnic origin, we considered that c.1A>G
might represent a founder mutation. This same mutation
was presented as part of a list of 50 candidate genes
associated with nonspecific intellectual disability,19 but
a haplotype and detailed phenotype were not available.
We analyzed the haplotype in families 542, 1414, and, 2013
Table 1. Phenotype of C12orf57-Mutated Individuals
Family ID 542-III-3 542-III-5 542-III-9 1414-III-1 1414-III-12 1183-III-5 1183-III-6 EZ1-III-5 EZ1-III-6 EZ1-III-8
Family Data
Consanguineous þ þ þ þ þ þ þ þ þ þ
Multiplex þ þ þ þ þ þ þ þ þ þ
Number of affected individuals 3 3 3 2 2 2 2 3 3 3
Clinical Findings
Dysmorphic facies    þ þ þ þ þ þ þ
Hypotonia þ þ þ  þ  þ þ þ þ
Microcephaly       þ   
Intellectual disability
or developmental delay
þ (severe) þ (severe) þ (severe) þ þ þ þ þ þ þ
Autistic features (absent
language, stereotypies)
þ þ þ þ þ þ þ þ þ þ
Seizures þ (PC) þ (GTC) þ (PC) þ  þ (GTC þ M) þ  þ þ
Electroencephalogram NA multifocal
discharges
NA þ generalized
spike wave
normal NA NA  intermittent
spike and slow
waves, slowing
spike and slow
wave discharges
Spasticity  þ þ þ  þ þ   
Visual abnormalities  þ abnormal VEP þ esotropia  þ optic
atrophy
 left micro-ophthalmia;
retinal/iris coloboma
  
Other systemic features  ASD ASD, mild PS,
conductive
hearing loss
ASD ASD distal
contractures;
elevated BG
diabetes; distal
contractures
  
MRI Findings
Corpus callosum hypoplasia hypoplasia absent hypoplasia absent hypoplasia absent with midline
colloid cyst
NA NA hypoplasia
Thalamic hypoplasia þ þ þ þ þ þ þ NA NA þ
Anterior commissure  þ (decreased)  þ (decreased)  NA þ (decreased) NA NA þ (decreased)
Ventriculomegaly  þ   þ þ þ NA NA þ
ON abnormalities      NA  NA NA 
Polymicrogyria      NA  NA NA 
Septum pellucidum abnormal þ þ þ þ þ þ  NA NA þ
Reduced white matter þ þ þ þ þ þ þ NA NA þ
Abbreviations are as follows: þ, present; , absent; NA, not available; ASD, atrial septal defect; BG, blood glucose; GTC, generalized tonic clonic; M, myoclonic seizures; ON, optic nerve; PC, partial complex; PS, pulmonary
stenosis; and VEP, visual evoked potentials.
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Figure 2. Brain Imaging Demonstrates a Specific CC Abnormality in C12orf57-Mutated Individuals
Upper image: midline sagittal MRI (where available). Lower image: axial MRI Images show CCH (arrows) in 542-III-3, 542-III-5, 1414-III-
1, 1183-III-5, and EZ1-III-5 and complete agenesis in 542-III-9, 1414-III-2, and 1183-III-6. The bottom panel shows a prominent fornix
(arrow) and unique appearance of the third ventricle (large arrowhead). Individual 1183-III-6 showed a colloid cyst, in addition to
complete agenesis of the CC. No sagittal images were available for individual 1414-III-1, only a CT was available for individual 1183-
III-5, and no imaging was available for individuals EZ1-III-5 and EZ1-III-6.1183 and identified a maximal potential sharing between
chr12:7050931 and chr12:7061354, or a distance of about
10 kilobases (Figure 1E), suggesting a common founder
mutation. (Family EZ1 sequencing was performed at a
clinical referral center and was not available for review.)
However, it is possible that the rare exonic variants
contributing to this haplotype were relatively recently
mutated (and that this is why they were not annotated
as common polymorphisms), so we additionally geno-
typed a series of SNPs surrounding the mutation. However,
we could not confirm a shared haplotype greater than this
interval (not shown). Thus, although the data suggest that
there might be a common founder mutation at this allele,
definitive evidence is lacking.
Little is known about C12orf57 function. With 381 bp
coding sequence, it predicts a 126 amino acid protein. In
order to determine the expression profile of C12orf57, we
retrotranscribed mRNA from a collection of human tissue
and induced pluripotent stem-cell-derived human neural
progenitor cells (NPCs). C12orf57 consensus cDNA was
quantified by real-time qPCR. Even though the resulting
product was detected in all tissues analyzed, fetal brain
was one of the tissues showing the most abundant
C12orf57 transcript (Figure 3A). The data suggest ubiqui-
tous expression in all human tissue tested and a relative
abundance of expression in fetal brain tissue.
C12orf57 falls within an evolutionarily conserved
gene-rich cluster in chr12:p13.31.20 According to the
UCSC Genome Browser (seeWeb Resources), the transcript
overlaps with the annotated 30-UTR of ATN1, encoding
Atrophin, which ismutated with a trinucleotide expansion
in DentatoRubral-PallidoLuysian Atrophy (DRPLA [MIM
125370]). Despite repeated attempts, we were unable
to amplify from cDNA any fragments that would indi-
cate that they are part of a common transcript (not
shown). In reviewing evidence for the overlap, we found
that it derives from a single spliced cDNA (GenBank396 The American Journal of Human Genetics 92, 392–400, March 7AB209345), which is probably a run-on transcript. We
conclude that the ATN1 transcript probably ends around
chr12:7051500, at least 500 bp prior to the first annotated
transcript of C12orf57, and that the two mRNAs are
completely separable.
Multiple annotated cDNAs for C12orf57 differ by alter-
native splicing, different exon boundaries, and truncation
of the 50 end, suggesting three possible alternative promo-
tors (represented by GenBank IDs AK310266, BI601148,
and BC009925). This is important because if there are
three separate start codons, it is possible that the start
codon substitution we identified might be complemented
by the other transcripts. However, three independent
experimental lines of evidence from the recent Encode
project21 suggest that the start codon we identified is the
primary start site for the gene. First, RNaseq data from
nine cell lines demonstrate active transcription of the
BC009925 region. Second, in cell line SK-N-MC, a neuroe-
pithelial cell line derived from a metastatic supra-orbital
human brain tumor, the RNA polymerase (RNApol) binds
predominantly to the BC009925 transcript start site. Third,
histone H3K4 trimethylation (H3K4me3), commonly asso-
ciated with actively transcribed regions, is enriched at the
BC009925 locus start site but not in the upstream
AK310266 or BI601148 locus start sites (ENCODE data in
the UCSC Genome Browser, year 5 update [see Web
Resources]; Figure 3B).22
In order to assess transcription and splicing directly in
human brain, we attempted to generate PCR products
from healthy human adult brain, fetal brain and NPC
cDNA compared with total genomic DNA using primers
complementary to the exons predicted by AK310266,
BI601148 and BC009925 (Figure 3C). After 30 cycles of
amplification, the six primer pairs generated products
with similar efficiency from genomic DNA. In the same
conditions, however, none of the AK3131266 and
BI601148 exon predicted products were detected in, 2013
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Figure 3. C12orf57 Transcript Expression in Human Tissues and Evidence for a Single Transcript Bearing the p.Met1? Substitution
in CCH
(A) qPCR of C12orf57 transcript normalized with GAPDH in adult human testis, liver, kidney, skeletal muscle, lung, heart, NPCs, cere-
bellum, forebrain, and fetal brain total cDNA. Error bars represent the standard deviation between two independent PCR products for
C12orf57 cDNA.
(B) ENCODE project track of UCSC Genome Browser shows transcriptional levels (from RNaseq), RNApol positioning, and H3K4me3
enrichment (from ChIPseq) for three C12orf57 cDNAs (represented by Genebank IDs AK310266, BI601148, and BC0092) with the
most relevant alternative start codon, suggesting that the transcript in which Met1 is substituted (red arrow) in CCH is the major active
transcript.
(C) Schematic representation of C12orf57 transcripts Primer positioning is indicated by green arrows, and the substituted Met1 is indi-
cated by a red arrow.
(D) PCR of C12orf57 exons in human adult brain, fetal brain, and NPCs from total poly-A reverse-transcribed cDNA compared with total
genomic DNA (bottom). Numbers refer to the primer pairs in (C).
(E) qPCR ofC12orf57 exon 2, representative of AK310266 and BI601148, and exon 4, representative of BC00925 transcripts, fromhuman
fetal brain cDNA.
(F) RT-PCR from human fetal brain cDNAwas performed with the indicated combination of primers and is consistent with the idea that
the Met1 substituted in CCH derives the major active transcript.human cDNA, whereas all of the BC009925 exon predicted
products were well represented. Quantification of the
transcripts by real time PCR showed that transcripts
represented by BC009925 were at least 100-times more
abundant in human fetal brain (Figure 3E). In addition
our attempts to identify alternative transcripts extending
the mRNA upstream by 50RACE were unsuccessful and
the predicted products for combination of primers that
target probable alternative 50 end transcirpts were not
detectable by RT-PCR (Figure 3F). We conclude that
BC009925 likely represents the major active transcript
from the C12orf57 locus in human neural tissue.
To determine whether the protein is stable upon transla-
tion, we cloned the human cDNA upstream of EGFP and
transfected COS7 cells. We found stable fluorescently
tagged protein signal with generalized cytoplasmic locali-
zation (Figure 4A). In order to validate this result inThe Amea disease-relevant cells we transduced NPCs with lentivirus
encoding EGFP-tagged C12ORF57 in the pINDUCER20
plasmid.23 This system allows dose-dependent doxycy-
cline-inducible expression. After a subsaturating dose of
doxycycline for 24 hr, EGFP signal was localized in the
cytoplasmic compartment, supporting a cytoplasmic local-
ization in neural cells (Figure 4B). To determine whether
the human mutation affects the protein, we introduced
the c.1A>G substitution into this lentiviral construct to
compare protein levels between the mutant and wild-
type. We found that the C12orf57 c.1A>G variant, which
results in a GUG start codon, was able to produce some
protein, although less efficiently than the wild-type
(Figures 4C–4D). In fact, the GUG start codon within an
optimal Kozak sequence is capable of initiating protein
synthesis, although with less efficiency than AUG.24
Whether this is true for C12orf57 c.1A>G within therican Journal of Human Genetics 92, 392–400, March 7, 2013 397
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Figure 4. C12ORF57-EGFP Localization Is Cytoplasmic, and c.1A>G Mutation Results in Reduced Translational Efficiency
(A) Cytoplasmic localization of C12ORF57-EGFP fusion protein compared with the diffuse localization of EGFP in transiently transfected
COS7 cells.
(B) Cytoplasmic localization of C12ORF57-EGFP in human NPCs. C12orf57-EGFP was subcloned in pINDUCER20 and transduced to
NPCs, expression was induced with 30 ng/ml doxycycline for 24 hr, and NPCs were immunostained with Nestin antibody (red).
(C) Comparison between wild-type and c.1A>G C12ORF57-EGFP translated protein levels on transduced NPCs 1 week after positive
selection with 200 mg/ml G418 and 24 hr after induction with 30 ng/ml doxycycline. Cells transduced with the mutant construct
show notably reduced protein levels.
(D) Immunoblot with EGFP antibody in wild-type and c.1A>G C12ORF57 transduced NPCs treated as in (C). Severely reduced protein
levels occur in the presence of the mutation. GAPDH was used as a loading control. The scale bar represents 20 mm.genomic context will require further investigtion, but the
possibility that the mutation results in reduced protein
levels could help explain the phenotypic variability.
With the major predicted protein in hand, we attempted
to identify both paralogs in humans as well as orthologs in
other species. A blastp search of the predicted 126 amino
acid protein against the human proteome yielded no
significant matches in the human protein database.
The closest overlap was with the huntingtin-interacting
protein 1-related protein (HIP1R, accession number
NP_003950.1, e-value 0.004, 25% maximum identity
over a 51 amino acid region), but blastp of HIP1R did not
yield C12ORF57, so the relationship is uncertain. More
interesting, though, was the phylogenetic analysis of
C12ORF57 across evolution; for this analysis, we used
a Grishin distance,25 a fast minimum evolution (FME)
algorithm,26 and FigTree software. There is evidence that
the C12orf57-encoded protein, called C10 (not to be
confused with chemokine CC10), is highly conserved as
a single copy across evolution. It is clearly traceable to
annotated vertebrates, bony fish, most sequenced insects
and cephalopods, and even some algae. Half of ten flies
treated with RNAi to C10 in a genome-wide screen showed
a nonspecific ‘‘malformation death’’ phenotype of the398 The American Journal of Human Genetics 92, 392–400, March 7notum or dorsal thorax region of the body,27 but other
species have not been subject to genetic perturbation.
In summary, we report a syndrome consisting of CC
hypoplasia involving enlargement of the third ventricle,
epilepsy, autistic features, and developmental delay.
The phenotypic spectrum of CCH, even within a single
family with a C12orf57 mutation, supports the idea that
complete agenesis is an end phenotype. It also supports
the idea that other genetic or environmental modifiers
impart an effect on the resultant CC morphology. The
C12orf57 locus produces a singlemajor transcript encoding
a 126 amino acid protein of unknown function but
cytoplasmic localization. Reduced protein production
associated with the identified mutation suggests a loss of
function as the disease mechanism. The conservation of
C12orf57 across evolution, even prior to the emergence
of cephalopods, suggests an ancient function, the disrup-
tion of which leaves the developing human brain particu-
larly vulnerable.Supplemental Data
Supplemental Data include three figures and one table and can be
found with this article online at http://www.cell.com/AJHG., 2013
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